Treatment strategy of EGFR-mutated non-small cell lung cancer

被引：1
作者：
Tanaka, Fumihiro [1 ]
Yoneda, Kazue [1 ]
Takenaka, Masaru [1 ]
Kuroda, Koji [1 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Surg Chest Surg 2, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2022年 / 14卷 / 03期
关键词：
OSIMERTINIB; PATIENT; MUTATIONS; SURGERY;
D O I：
10.21037/jtd-22-177
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：602 / 606
页数：5
相关论文
共 50 条
  • [21] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [22] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [23] Early dose reduction of osimertinib in advanced EGFR-mutated non-small cell lung cancer
    Ferreira, Marion
    Ebia, Matthew I.
    Reckamp, Karen L.
    ANTI-CANCER DRUGS, 2024, 35 (07) : 672 - 679
  • [24] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [25] Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
    Kunimasa, Kei
    Kamada, Risa
    Oka, Toru
    Oboshi, Makiko
    Kimura, Madoka
    Inoue, Takako
    Tamiya, Motohiro
    Nishikawa, Tatsuya
    Yasui, Taku
    Shioyama, Wataru
    Nishino, Kazumi
    Imamura, Fumio
    Kumagai, Toru
    Fujita, Masashi
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 1 - 10
  • [26] Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer
    Chevallier, Mathieu
    Tsantoulis, Petros
    Addeo, Alfredo
    Friedlaender, Alex
    CANCER GENOMICS & PROTEOMICS, 2020, 17 (05) : 597 - 603
  • [27] Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non-Small Cell Lung Cancer
    Wang, Huaying
    Lin, Lie
    Liang, Chuqiao
    Pang, Jiaohui
    Yin, Jiani C.
    Zhang, Junli
    Shao, Yang
    Sun, Chengming
    Guo, Renhua
    JCO PRECISION ONCOLOGY, 2024, 8
  • [28] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [29] Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis
    Chang, Xiaoyan
    Wang, Chenghao
    Zhang, Linyou
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 1703 - 1719
  • [30] Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Liang, Huan-Wei
    Liu, Yang
    Pan, Xin-Bin
    AGING-US, 2024, 16 (01): : 857 - 871
12345